Yi Xia

机构：Sun Yat-sen University, Sun Yat-sen University Cancer Center, Jiangsu Province Hospital, CTI BioPharma (Italy), Nanjing Medical University · ORCID：0000-0002-2197-5865

发表论文 245 篇 · 总被引 4323 次 · h-index 37

代表论文

• First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Haematology · 被引 33)
• Single‐Cell Analysis Reveals Malignant Cells Reshape the Cellular Landscape and Foster an Immunosuppressive Microenvironment of Extranodal NK/T‐Cell Lymphoma (2023 · Advanced Science · 被引 30)
• Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial (2023 · BMC Medicine · 被引 15)
• Combination of Mitoxantrone Hydrochloride Liposome with Tislelizumab in Patients with Relapsed or Refractory NK/T Cell Lymphoma: A Phase Ib/Ⅱ Clinical Trial (2023 · Blood · 被引 6)
• CircTADA2A stabilizes p53 via interacting with TRIM28 and suppresses the maintenance of FLT3-ITD acute myeloid leukemia (2025 · Leukemia · 被引 4)
• 174P Intracranial (IC) activity of ivonescimab (ivo) alone or in combination with platinum doublet chemotherapy (PC) in patients (Pts) with advanced non-small cell lung cancer (aNSCLC) and brain metastases (BMs) (2024 · ESMO Open · 被引 4)